DeCure for Microcephaly 9, primary, autosomal recessive
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for microcephaly 9, primary, autosomal recessive — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMicrocephaly 9, primary, autosomal recessive maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for microcephaly 9, primary, autosomal recessive is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Autosomal recessive primary microcephaly (MCPH) is a genetically heterogeneous neurodevelopmental disorder defined by a head circumference more than three standard deviations below the mean at birth, reduced brain volume, and intellectual disability. Inconsistent features include hyperactivity, expressive speech disorder, and epilepsy. Imaging shows brains of normal architecture but reduced size, particularly in the cerebral cortex, with simplified cortical structure and slightly reduced white matter volume. Some patients show periventricular neuronal heterotopias suggesting neuronal migration defects. The 2008 review notes that neuropathological studies are rare and were performed before genetic diagnosis was possible; available histology from infants with Microcephalia vera shows significantly reduced brain volume with preserved convolution pattern and no myelination disturbances, plus cytoarchitectonic anomalies predominantly in the first two cortical layers, including compact cell clusters in the second layer.
A 1988 report describes a large family with 13 affected members across three generations showing autosomal dominant isolated microcephaly without other dysmorphic or neurological abnormalities. The pedigree confirms autosomal dominant inheritance with incomplete penetrance, including male-to-male transmission and a skipped generation. The authors stress that this uncomplicated type should be distinguished from other dominantly inherited microcephaly forms. This is a separate inheritance pattern from the autosomal recessive form that is the focus of the 2017 and 2008 reviews.
No drug treatment, intervention, or clinical trial is mentioned in any of these abstracts. The 2017 update provides an overview for clinicians but offers no therapeutic data. The 2008 review explicitly states that it is not known whether the brain pathology results from defective cell proliferation, differentiation, migration, or increased cell death, and calls for more neuropathological studies. What is missing is any preclinical or clinical research into pharmacological intervention, any animal model testing of compounds, any patient stratification by specific MCPH gene mutation, and any funding for drug-repurposing screens or trials.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neuropediatrics · 2017 · 91 citations
Autosomal Recessive Primary Microcephaly (MCPH): An Update
AbstractAutosomal recessive primary microcephaly (MCPH; MicroCephaly Primary Hereditary) is a genetically heterogeneous neurodevelopmental disorder characterized by a significantly reduced head circumference present already at birth and intellectual disability. Inconsistent features include hyperactivity, an expressive speech disorder, and epilepsy. Here, we provide a brief overview on this rare disorder pertinent for clinicians.
AbstractA large family (13 affected members in three generations) is reported in which isolated microcephaly occurred without any other dysmorphic or neurological abnormalities. The family pedigree confirms the autosomal dominant mode of inheritance with incomplete penetrance, including one example of male to male transmission and the occurrence of a non-manifesting heterozygote resulting in a 'skipped generation'. There is considerable variation in the phenotypic expression of autosomal dominant microcephaly. This isolated (uncomplicated) type of microcephaly should be distinguished from other well defined, dominantly inherited forms of microcephaly.
Neuropathologic findings in patients with primary autosomal recessive microcephaly
AbstractAutosomal recessive primary microcephaly (MCPH, syn. Microcephalia vera) is a rare, genetically heterogeneous disease, in which patients exhibit microcephaly by the 32nd week of gestation. Genetic causes of MCPH subtypes 1–6 include mutations in genes encoding microcephalin (MCPH1), cyclin dependent kinase 5 regulatory associated protein 2 CDK5RAP2 (MCPH3), abnormal spindle-like, microcephaly associated ASPM (MCPH5), centromeric protein J CENPJ (MCPH6) as well as linkage to the two loci 19q13.1–13.2 (MCPH2) and 15q15-q21 (MCPH4). Severe microcephaly is characterized by a significantly reduced occipito-frontal head circumference (OCF) of more than three standard deviations below the mean for age, sex, and ethnicity. Microcephaly correlates closely with reduced brain volume and mental retardation, but patients with MCPH typically do not have further neurological findings. Imaging studies show brains of normal architecture but of reduced size. The latter is particularly evident in the cerebral cortex, which shows a simplified cerebral cortex structure, and there is also a slightly reduced white matter volume. Individual patients with MCPH provide evidence of periventricular neuronal heterotopias suggesting neuronal migration defects. It is not known whether the brain pathology in patients with MCPH is the result of defective cell proliferation/differentiation, cell migration and/or increased cell death. Neuropathological studies, which are rare and were performed at a time when a genetic diagnosis could not be performed, are thus highly warranted. Here, we summarize current knowledge on histological findings in MCPH patients. Infants with Microcephalia vera exhibited a significantly reduced brain volume with an almost preserved convolution pattern and no myelination disturbances. Cytoarchitectonic anomalies, seen predominantly in the first two cortical layers, included the appearance of compact cell clusters in the second layer. This can be interpreted as being indicative of a proliferation/differentiation and/or migration defect.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
